The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 05, 2019
Filed:
Oct. 21, 2016
Applicant:
Intrexon Actobiotics NV, Zwijnaarde, BE;
Inventors:
Pieter Rottiers, De Pinte, BE;
Veerle Snoeck, Zingem, BE;
Assignee:
INTREXON ACTOBIOTICS NV, Zwijnaarde, BE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/39 (2006.01); A61K 39/35 (2006.01); A61K 35/747 (2015.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); A61K 35/74 (2015.01); A61K 39/395 (2006.01); A23K 10/18 (2016.01); A23K 50/20 (2016.01); A23K 50/10 (2016.01); A23K 50/30 (2016.01); A23K 50/40 (2016.01); A23K 50/50 (2016.01); A23L 33/135 (2016.01); C07K 16/28 (2006.01); A61K 36/064 (2006.01);
U.S. Cl.
CPC ...
A61K 39/35 (2013.01); A23K 10/18 (2016.05); A23K 50/10 (2016.05); A23K 50/20 (2016.05); A23K 50/30 (2016.05); A23K 50/40 (2016.05); A23K 50/50 (2016.05); A23L 33/135 (2016.08); A61K 35/74 (2013.01); A61K 35/747 (2013.01); A61K 38/2066 (2013.01); A61K 39/0008 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); C07K 16/2809 (2013.01); A61K 36/064 (2013.01); A61K 2039/505 (2013.01); A61K 2039/52 (2013.01); A61K 2039/523 (2013.01); A61K 2039/541 (2013.01); A61K 2039/542 (2013.01); A61K 2039/543 (2013.01); A61K 2039/544 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/55544 (2013.01); A61K 2039/577 (2013.01);
Abstract
The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3and/or IL-10 and/or TGF-β producing regulatory T-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism.